The KICDC/Defy Pitch Competition Final Round took place in Washington, D.C. on November 1st.
Out of 18 teams competing in the Bio/Life Science category, 6 finalists were selected to present IR pitches on their respective drugs, medical devices, and healthcare services under development. RudaCure proudly claimed 1st place among these finalists.
Following the event, CEO Yongho Kim and EVP Dong-hyun Kim are scheduled to attend the American Academy of Ophthalmology (AAO) conference, and will also hold a meeting in San Francisco with Senju, which has expressed interest in licensing RCI001 technology.
BD representative Harris Hasrol is scheduled to attend Bio-EU.
We believe that achieving these excellent results despite the physical and mental challenges of an extended overseas business trip is the product of the united strength of all RudaCure employees.
We will continue to strive to deliver even more achievements going forward.